News | EP Mapping and Imaging Systems | July 07, 2016

Abbott Announces Positive Clinical Results with FIRM-Guided Rotor Ablation for Atrial Fibrillation

Trio of studies presented at Cardiostim conference support technique that allows more individualized treatment of cardiac arrhythmias

Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016

July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits associated with focal impulse rotor modulation (FIRM)-guided rotor ablation for atrial fibrillation. The investigator-sponsored studies, which evaluated the use of Abbott’s RhythmView technology, were presented at the Cardiostim-EHRA Europace 2016 conference, June 8-11 in Nice, France.

FIRM-guided therapy enables physicians to identify and locate rotors – unique patient-specific sources that sustain serious heart rhythm disorders, including atrial fibrillation. With the ability to visualize individual rotors, physicians can tailor treatment approaches for each patient.

“The latest data presented at Cardiostim adds to a growing body of clinical evidence in support of the FIRM-guided approach in combination with conventional ablation, with the goals of optimizing treatment planning for atrial fibrillation and improving long-term results for our patients,” said Prof. Stefan Spitzer of the Praxisklinik Herz und Gefäße in Dresden, Germany, who authored one of the data presentations at the conference. “I look forward to additional analyses that further investigate this important therapy option.”

The studies presented at Cardiostim investigated the benefits associated with FIRM-guided rotor ablation when combined with the traditional procedure for atrial fibrillation. Key findings include:

  • Spitzer presented results from 58 patients finding 80.8 percent of patients free from atrial fibrillation at 12 months post-treatment with FIRM-guided ablation for redo cases of persistent atrial fibrillation, with 83 percent of patients having long-standing persistent atrial fibrillation;
  • Tamas Szili-Torok, M.D., Rotterdam, Netherlands, presented the first results from the European-Focal Impulse and Rotor Modulation Registry (E-FIRM) of 138 patients showing 78 percent and 72 percent of patients in sinus rhythm following treatment with the FIRM-guided ablation at six and 12 months, respectively; and
  • Haroon Rashid, M.D., Falls Church, Va., shared data examining the relationship between stable rotors and obstructive sleep apnea in 47 patients, showing 78.6 percent of patients in sinus rhythm after FIRM-guided ablation, despite the presence of obstructive sleep apnea.

During a FIRM-guided rotor ablation procedure for atrial fibrillation, physicians use Abbott’s proprietary technology to identify and visualize rotors, important sustaining mechanisms of cardiac arrhythmias. Because arrhythmias develop as a result of both electrical and anatomic abnormalities, every patient needs to be individually diagnosed and treated. The system offers a patient-specific solution that enables physicians, for the very first time, to identify and ablate the unique sources that sustain serious heart rhythm disorders.

Read about first reports on the FIRM rotor mapping technique at HRS.

 

For more information: www.abbott.com

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM)| February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Overlay Init